212 related articles for article (PubMed ID: 22134072)
1. Worse disease-free survival in never-smokers with ALK+ lung adenocarcinoma.
Yang P; Kulig K; Boland JM; Erickson-Johnson MR; Oliveira AM; Wampfler J; Jatoi A; Deschamps C; Marks R; Fortner C; Stoddard S; Nichols F; Molina J; Aubry MC; Tang H; Yi ES
J Thorac Oncol; 2012 Jan; 7(1):90-7. PubMed ID: 22134072
[TBL] [Abstract][Full Text] [Related]
2. ALK+ lung adenocarcinoma in never smokers and long-term ex-smokers: prevalence and detection by immunohistochemistry and fluorescence in situ hybridization.
Williams AS; Greer W; Bethune D; Craddock KJ; Flowerdew G; Xu Z
Virchows Arch; 2016 Nov; 469(5):533-540. PubMed ID: 27562706
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathologic implication of ALK rearrangement in surgically resected lung cancer: a proposal of diagnostic algorithm for ALK-rearranged adenocarcinoma.
Paik JH; Choi CM; Kim H; Jang SJ; Choe G; Kim DK; Kim HJ; Yoon H; Lee CT; Jheon S; Choe JY; Chung JH
Lung Cancer; 2012 Jun; 76(3):403-9. PubMed ID: 22129856
[TBL] [Abstract][Full Text] [Related]
4. Responses to crizotinib in patients with ALK-positive lung adenocarcinoma who tested immunohistochemistry (IHC)-positive and fluorescence in situ hybridization (FISH)-negative.
Ma D; Wang Z; Yang L; Mu X; Wang Y; Zhao X; Li J; Lin D
Oncotarget; 2016 Sep; 7(39):64410-64420. PubMed ID: 27418132
[TBL] [Abstract][Full Text] [Related]
5. A comparative analysis of immunohistochemistry and fluorescent
Wagle PB; Jambhekar NA; Kumar R; Prabhash K; Pramesh CS; Desai SB; Noronha V; Karimundackal G; Shah A; Joshi A; Laskar SG; Jiwnani S; Pai T; Agarwal JP
Indian J Cancer; 2017; 54(1):148-154. PubMed ID: 29199679
[TBL] [Abstract][Full Text] [Related]
6. Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer: correlation with fluorescence in situ hybridization.
Paik JH; Choe G; Kim H; Choe JY; Lee HJ; Lee CT; Lee JS; Jheon S; Chung JH
J Thorac Oncol; 2011 Mar; 6(3):466-72. PubMed ID: 21258247
[TBL] [Abstract][Full Text] [Related]
7. Frequency of ALK Rearrangement by FISH Testing and its Correlation with ALK-IHC in Adenocarcinoma of Primary Lung Origin.
Moatter S; Anwar N; Moatter T; Pervez S
Asian Pac J Cancer Prev; 2018 Jun; 19(6):1735-1738. PubMed ID: 29938474
[TBL] [Abstract][Full Text] [Related]
8. Prevalence and clinical outcomes for patients with ALK-positive resected stage I to III adenocarcinoma: results from the European Thoracic Oncology Platform Lungscape Project.
Blackhall FH; Peters S; Bubendorf L; Dafni U; Kerr KM; Hager H; Soltermann A; O'Byrne KJ; Dooms C; Sejda A; Hernández-Losa J; Marchetti A; Savic S; Tan Q; Thunnissen E; Speel EJ; Cheney R; Nonaka D; de Jong J; Martorell M; Letovanec I; Rosell R; Stahel RA
J Clin Oncol; 2014 Sep; 32(25):2780-7. PubMed ID: 25071109
[TBL] [Abstract][Full Text] [Related]
9. Anaplastic lymphoma kinase status in lung cancers: An immunohistochemistry and fluorescence
Murthy SS; Rajappa SJ; Gundimeda SD; Mallavarapu KM; Ayyagari S; Yalavarthi P; Fonseca D; Paliwal P; Nair H; Koppula V; Raju K; Rao ST
Indian J Cancer; 2017; 54(1):231-235. PubMed ID: 29199697
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic value of a novel fully automated immunochemistry assay for detection of ALK rearrangement in primary lung adenocarcinoma.
Ying J; Guo L; Qiu T; Shan L; Ling Y; Liu X; Lu N
Ann Oncol; 2013 Oct; 24(10):2589-2593. PubMed ID: 23904459
[TBL] [Abstract][Full Text] [Related]
11. Detection of ALK rearrangement by immunohistochemistry in lung adenocarcinoma and the identification of a novel EML4-ALK variant.
To KF; Tong JH; Yeung KS; Lung RW; Law PP; Chau SL; Kang W; Tong CY; Chow C; Chan AW; Leung LK; Mok TS
J Thorac Oncol; 2013 Jul; 8(7):883-91. PubMed ID: 23625156
[TBL] [Abstract][Full Text] [Related]
12. Analysis of clinical characteristics and prognosis of patients with anaplastic lymphoma kinase-positive and surgically resected lung adenocarcinoma.
Tao H; Cai Y; Shi L; Tang J; Liu Z; Wang Z; Bai L; Liu Z
Thorac Cancer; 2017 Jan; 8(1):8-15. PubMed ID: 27779369
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical screening and fluorescence in situ hybridization confirmation of ALK translocation in lung adenocarcinoma and its clinicopathological significance: a single-center large-scale investigation of Chinese patients.
Wang WY; Liang DN; Yao WQ; Wu WL; Li JN; Chen M; Liao DY; Zhang M; Li GD
Hum Pathol; 2014 Jul; 45(7):1414-22. PubMed ID: 24775606
[TBL] [Abstract][Full Text] [Related]
14. Antibody 1A4 with routine immunohistochemistry demonstrates high sensitivity for ALK rearrangement screening of Chinese lung adenocarcinoma patients: A single-center large-scale study.
Wang Q; Zhao L; Yang X; Wei S; Zeng Y; Mao C; Lin L; Fu P; Lyu L; Li Z; Xiao H
Lung Cancer; 2016 May; 95():39-43. PubMed ID: 27040850
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathologic characteristics and outcomes of patients with anaplastic lymphoma kinase-positive advanced pulmonary adenocarcinoma: suggestion for an effective screening strategy for these tumors.
Koh Y; Kim DW; Kim TM; Lee SH; Jeon YK; Chung DH; Kim YW; Heo DS; Kim WH; Bang YJ
J Thorac Oncol; 2011 May; 6(5):905-12. PubMed ID: 21358343
[TBL] [Abstract][Full Text] [Related]
16. ALK Protein Analysis by IHC Staining after Recent Regulatory Changes: A Comparison of Two Widely Used Approaches, Revision of the Literature, and a New Testing Algorithm.
Marchetti A; Di Lorito A; Pace MV; Iezzi M; Felicioni L; D'Antuono T; Filice G; Guetti L; Mucilli F; Buttitta F
J Thorac Oncol; 2016 Apr; 11(4):487-95. PubMed ID: 26916631
[TBL] [Abstract][Full Text] [Related]
17. Evaluating the effectiveness of RNA in-situ hybridization for detecting lung adenocarcinoma with anaplastic lymphoma kinase rearrangement.
Nakajima N; Yoshizawa A; Kondo K; Rokutan-Kurata M; Hirata M; Furuhata A; Sumiyoshi S; Sonobe M; Menju T; Momose M; Fujimoto M; Date H; Haga H
Histopathology; 2017 Jul; 71(1):143-149. PubMed ID: 28231386
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants.
Cha YJ; Kim HR; Shim HS
J Transl Med; 2016 Oct; 14(1):296. PubMed ID: 27756333
[TBL] [Abstract][Full Text] [Related]
19. EML4-ALK translocation predicts better outcome in lung adenocarcinoma patients with wild-type EGFR.
Wu SG; Kuo YW; Chang YL; Shih JY; Chen YH; Tsai MF; Yu CJ; Yang CH; Yang PC
J Thorac Oncol; 2012 Jan; 7(1):98-104. PubMed ID: 22124476
[TBL] [Abstract][Full Text] [Related]
20. ALK-rearranged pulmonary adenocarcinoma in Thai Patients: From diagnosis to treatment efficacy.
Incharoen P; Reungwetwattana T; Saowapa S; Kamprerasart K; Pangpunyakulchai D; Arsa L; Jinawath A
World J Surg Oncol; 2016 May; 14():139. PubMed ID: 27142166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
